These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15319016)

  • 21. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
    Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
    J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.
    Hoare P; Remschmidt H; Medori R; Ettrich C; Rothenberger A; Santosh P; Schmit M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):305-9. PubMed ID: 16220214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
    Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
    Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study.
    Wilens T; McBurnett K; Stein M; Lerner M; Spencer T; Wolraich M
    J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1015-23. PubMed ID: 16175106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick EO; Surman C; Doyle R; Hammerness P; Michel E; Martin J; Spencer TJ
    BMC Psychiatry; 2007 Sep; 7():49. PubMed ID: 17868455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J; Mick E; Fried R; Wilner N; Spencer TJ; Faraone SV
    Eur Neuropsychopharmacol; 2011 Jul; 21(7):508-15. PubMed ID: 21303732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.
    Castellanos FX; Giedd JN; Elia J; Marsh WL; Ritchie GF; Hamburger SD; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):589-96. PubMed ID: 9136492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.